FKW00GA

Last updated

FKW00GA
Clinical data
Other namesFKW-00GA; TGW00AA; TGW-00AA; TGWOOAA; TGW-OOAA
Routes of
administration 		Oral [1]
Drug class Serotonin 5-HT1A receptor partial agonist; Serotonin 5-HT2A receptor antagonist [1] [2]

FKW00GA, also known as TGW00AA, is a serotonin 5-HT1A receptor partial agonist and serotonin 5-HT2A receptor antagonist which is under development for the treatment of generalized anxiety disorder, social phobia (social anxiety disorder), and sexual dysfunction. [1] [3] [2] [4] [5] [6] It is taken by mouth. [1]

As of June 2021, FKW00GA is in phase 2 clinical trials for generalized anxiety disorder, social phobia, and sexual dysfunction. [1] [3] It has been in phase 2 clinical trials since at least 2018. [6] The drug is under development by Fabre-Kramer Pharmaceuticals. [1] [3] [2] FKW00GA is a small molecule, but its chemical structure does not yet seem to have been released. [1] [3]

See also

References

  1. 1 2 3 4 5 6 7 "FKW 00GA". AdisInsight. 15 June 2021. Retrieved 29 October 2024.
  2. 1 2 3 Sartori SB, Singewald N (December 2019). "Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders". Pharmacology & Therapeutics. 204 107402. doi: 10.1016/j.pharmthera.2019.107402 . PMID   31470029.
  3. 1 2 3 4 "Delving into the Latest Updates on TGW00AA with Synapse". Synapse. 19 September 2024. Retrieved 29 October 2024.
  4. ↑ Farmer M, Yoon H, Goldstein I (August 2016). "Future Targets for Female Sexual Dysfunction". The Journal of Sexual Medicine. 13 (8): 1147–1165. doi:10.1016/j.jsxm.2016.05.016. PMID   27436073.
  5. ↑ Fagan HA, Baldwin DS (June 2023). "Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions". Expert Review of Neurotherapeutics. 23 (6): 535–548. doi:10.1080/14737175.2023.2211767. PMID   37183813.
  6. 1 2 Staroń J, Bugno R, Hogendorf AS, Bojarski AJ (September 2018). "5-HT1A receptor ligands and their therapeutic applications: review of new patents". Expert Opinion on Therapeutic Patents. 28 (9): 679–689. doi:10.1080/13543776.2018.1514011. PMID   30124346.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.